Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2024-04-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于公司及控股公司向金融机构申请授信额度及公司合并报表范围内担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company (亿帆医药股份有限公司) regarding the application for credit limits from financial institutions and the guarantee limits within the scope of consolidated financial statements. It includes extensive financial data, guarantee amounts, asset-liability ratios, and board meeting resolutions. The document is not a full financial report but an announcement about financing and guarantee arrangements. It does not contain quarterly or annual financial statements or earnings highlights but focuses on capital and financing activities, specifically credit and guarantee limits. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 10,000 characters, indicating it is a full announcement, not a brief notice or report publication announcement.
2024-04-19 Chinese
关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (Lixin CPA Firm) as the auditor for the company for the 2024 fiscal year. It details the firm's background, qualifications, audit fees, and the approval process by the board and audit committee. It does not contain any financial statements or audit reports themselves, but rather the decision and procedural information about the auditor appointment. This fits the category of an Audit Report / Information announcement related to auditor appointment and audit firm information, but since it is not the audit report itself, it is best classified as an Audit Report / Information (AR). The document length is over 5,000 characters and contains substantive information about the audit firm and appointment process, not just a brief notice or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). FY 2024
2024-04-19 Chinese
《公司章程》修正案
Governance Information Classification · 95% confidence The document is a detailed amendment to the company's Articles of Association (公司章程) of 亿帆医药股份有限公司, including governance rules, board and shareholder meeting procedures, director qualifications, and profit distribution policies. It references compliance with stock exchange rules and regulatory guidelines, and it is dated April 2024. The content is focused on governance structure and internal company rules rather than financial results or audit opinions. It is not a report of financial performance, earnings, or audit, nor is it a simple announcement or voting result. The document is a governance-related filing detailing internal rules and board structure changes, which fits the Governance Information (CGR) category.
2024-04-19 Chinese
关于调整公司组织架构的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the company regarding an adjustment to its organizational structure, approved by the board of directors. It includes a description of the board meeting and the authorization for management to implement the changes. There is no financial data, no mention of annual or quarterly reports, no voting results, no legal proceedings, no capital changes, and no other report types. The content is about management and board-level organizational changes, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Therefore, the best classification is MANG with high confidence.
2024-04-19 Chinese
2023年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2023年度监事会工作报告" which translates to "2023 Supervisory Board Work Report". It details the supervisory board's activities, meetings, opinions on financial reports, internal controls, related party transactions, and plans for 2024. It references the review and supervision of the company's 2023 financial reports (annual, half-year, quarterly) and audit reports but does not itself contain the full financial statements or detailed financial data. The document length is 3516 characters, which is relatively short and consistent with a summary or report rather than a full annual report or interim report. The content is focused on the supervisory board's oversight and opinions rather than presenting the company's full financial performance or detailed financial statements. Therefore, this document is best classified as an Audit Report / Information (AR) because it is a standalone supervisory board report providing audit-related oversight and opinions on financial and internal control matters, distinct from the full Annual Report (10-K) or Interim Report (IR). FY 2023
2024-04-19 Chinese
董事会关于会计政策变更追溯调整财务报表数据的专项说明
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from the board of directors regarding retrospective adjustments to financial statement data due to a change in accounting policy, specifically related to deferred income tax treatment under a new accounting standard effective from January 1, 2023. It references an audit by an accounting firm and provides detailed financial impact tables for the adjustments. The document is relatively short (1756 characters) and focuses on explaining the accounting policy change and its effects on prior financial statements. It is not a full annual report or interim report but a specific disclosure about accounting policy changes and retrospective adjustments. This type of document is typically classified as a Regulatory Filing (RNS) because it is an official regulatory announcement about accounting policy changes and restatements, not the full audit report or annual report itself. It does not fit the definitions of Annual Report (10-K), Audit Report (AR), or Interim Report (IR), nor is it a simple announcement of report publication (RPA) since it contains substantive financial data and board opinion. Therefore, the best classification is Regulatory Filings (RNS).
2024-04-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.